BioCentury
ARTICLE | Clinical News

Undisclosed HuCal antibody for ophthalmology: Phase I started

August 9, 2010 7:00 AM UTC

Novartis began a Phase I trial of an undisclosed HuCAL antibody. The start triggers an undisclosed milestone payment to MorphoSys, which is using its HuCAL GOLD technology to discover and optimize ant...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article